The DOI matches its Crossref record; 67 of the 69 references it cites were found in a registry or an index.
The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study
Open accessAbstract
Rodent studies indicate that ghrelin receptor blockade reduces alcohol consumption. However, no ghrelin receptor blockers have been administered to heavy alcohol drinking individuals. Therefore, we evaluated the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and behavioral effects of a novel ghrelin receptor inverse agonist, PF-5190457, when co-administered with alcohol. We tested the effects of PF-5190457 combined with alcohol on locomotor activity, loss-of-righting reflex (a measure of alcohol sedative actions), and on blood PF-5190457 concentrations in rats. Then, we performed a single-blind, placebo-controlled, within-subject human study with PF-5190457 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.i.d.). Twelve heavy drinkers during three identical visits completed an alcohol administration session, subjective assessments, and an alcohol cue-reactivity procedure, and gave blood samples for PK/PD testing. In rats, PF-5190457 did not interact with the effects of alcohol on locomotor activity or loss-of-righting reflex. Alcohol did not affect blood PF-5190457 concentrations. In humans, all adverse events were mild or moderate and did not require discontinuation or dose reductions. Drug dose did not alter alcohol concentration or elimination, alcohol-induced stimulation or sedation, or mood during alcohol administration. Potential PD markers of PF-5190457 were acyl-to-total ghrelin ratio and insulin-like growth factor-1. PF-5190457 (100 mg b.i.d.) reduced alcohol craving during the cue-reactivity procedure. This study provides the first translational evidence of safety and tolerability of the ghrelin receptor inverse agonist PF-5190457 when co-administered with alcohol. PK/PD/behavioral findings support continued research of PF-5190457 as a potential pharmacological agent to treat alcohol use disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a small initial clinical trial involving 12 heavy drinkers, PF-5190457, when compared to a placebo, lessened alcohol cravings and reactivity to alcohol-related cues.”
From A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, when used in conjunction with alcohol, PF-5190457 proved safe and well tolerated, showing no adverse interactions between the drug and alcohol”
From A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder (2024) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479
Small sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552
A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release
Howard, A., Feighner, S., Cully, D., Arena, J. P., Liberator, P., Rosenblum, C., Hamelin, M., Hreniuk, D. L., Palyha, O., Anderson, J., et al. (1996) · Science · doi:10.1126/science.273.5277.974 · Cited by 2,106
The reinstatement model of drug relapse: history, methodology and major findings
Shaham, Y., Shalev, U., Lu, L., de Wit, H., & Stewart, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1224-x · Cited by 1,615
The Novel Hypothalamic Peptide Ghrelin Stimulates Food Intake and Growth Hormone Secretion
Wren, A. M., Small, C. J., Ward, H. L., Murphy, K. G., Dakin, C. L., Taheri, S., Kennedy, A. R., Roberts, G. H., Morgan, D. G. A., Ghatei, M. A., et al. (2000) · Endocrinology · doi:10.1210/endo.141.11.7873 · Cited by 1,593
Müller, T. D., Nogueiras, R., Andermann, M. L., Andrews, Z. B., Anker, S. D., Argente, J., Batterham, R. L., Benoit, S. C., Bowers, C. Y., Broglio, F., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.03.005 · Cited by 1,034
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
The reliability of the Alcohol Timeline Followback when administered by telephone and by computer
Sobell, L. C., Brown, J., Leo, G. I., & Sobell, M. B. (1996) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(96)01263-x · Cited by 750
Development and Validation of the Biphasic Alcohol Effects Scale
Martin, C. S., Earleywine, M., Musty, R. E., Perrine, M. W., & Swift, R. M. (1993) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1993.tb00739.x · Cited by 683
Development and Initial Validation of a Measure of Drinking Urges in Abstinent Alcoholics
Bohn, M. J., Krahn, D. D., & Staehler, B. A. (1995) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1995.tb01554.x · Cited by 641
Cited by
Sorted by citations
Carvalho, A. F., Heilig, M. A., Perez, A., Probst, C., & Rehm, J. T. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31775-1 · Cited by 714
Self-citationInterventions and Manipulations of Interoception
Weng, H. Y., Feldman, J. L., Leggio, L., Napadow, V., Park, J., & Price, C. J. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.09.010 · Cited by 250
Self-citationNovel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
Ghrelin: From a gut hormone to a potential therapeutic target for alcohol use disorder
Farokhnia, M., Faulkner, M. L., Piacentino, D., Lee, M. R., & Leggio, L. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.02.008 · Cited by 107
Self-citationGut-brain axis and addictive disorders: A review with focus on alcohol and drugs of abuse
Jerlhag, E. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.005 · Cited by 92
Metadata
- Authors
- Lee, M. R., Tapocik, J. D., Ghareeb, M., Schwandt, M. L., Dias, A. A., Le, A. N., Cobbina, E., Farinelli, L. A., Bouhlal, S., Farokhnia, M., Heilig, M., Akhlaghi, F., & Leggio, L.
- Affiliations
- National Institutes of Health (US)
- University of Rhode Island (US)
- Linköping University (SE)
- Corresponding author
- Leggio, Lorenzo
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2018-05-04
- Volume
- 25
- Issue
- 2
- Pages
- 461-475
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC6215751
- OpenAlex
- W2799409941
- Cited by
- 129
- References
- 69
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 22 · 2023: 12 · 2022: 19 · 2021: 16 · 2020: 15 · 2019: 14 · 2018: 10
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Journal of Media Literacy Education (submittedVersion, cc-by)
- Funders
- National Institutes of Health (UH2TR000963, UH3TR000963)
- National Institute on Alcohol Abuse and Alcoholism (ZIAAA000218)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- alcoholism, alcohol craving, alcohol cue reactivity, pharmacokinetics, pharmacodynamics, drug safety and tolerability, heavy drinkers, insulin-like growth factor I, locomotor activity
- MeSH terms
- Adult, Alcohol Drinking, Ethanol, Alcoholic Intoxication, Alcoholism, Animals, Azetidines, Female, Humans, Male, Middle Aged, Research Design, Spiro Compounds, Single-Blind Method, Rats, Wistar, Rats, Ghrelin, Receptors, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
